natgillin/translations-raw huggingface dataset:
In patients taking warfarin who are treated with bivalirudin, International Normalised Ratio (INR) monitoring should be considered to ensure that it returns to pre-treatment levels following discontinuation of bivalirudin treatment.
U bolesnika koji uzimaju varfarin, a liječeni su bivalirudinom, potrebno je se razmotriti mjerenje INRa (International Normalised Ratio, međunarodni normalizirani omjer) kako bi se osiguralo da se nakon prestanka liječenja bivalirudinom INR vrati na razinu jednaku onoj prije liječenja.
In REPLACE-2, bleeding data were collected separately from adverse events.
U REPLACE-2 ispitivanju podaci o krvarenju sakupljani su odvojeno od nuspojava.
It is unknown whether bivalirudin is excreted in human milk.
Nije poznato izlučuje li se bivalirudin u majčino mlijeko.
Interaction studies have been conducted with platelet inhibitors, including acetylsalicylic acid, ticlopidine, clopidogrel, abciximab, eptifibatide, or tirofiban.
Ispitivanja interakcija provedena su s inhibitorima trombocita, uključujući acetilsalicilnu kiselinu, tiklopidin, klopidogrel, abciksimab, eptifibatid i tirofiban.
The mean steadystate concentration of bivalirudin following a constant intravenous infusion of 2.5 mg/kg/h is 12.4 µg/ml.
Srednja vrijednost koncentracije bivalirudina u stanju ravnoteže nakon konstantne intravenske infuzije od 2,5 mg/kg/satu je 12,4 µg/ml.
Data from 366 patients indicates that the ACT is unaffected by concomitant treatment with a GP IIb/IIIa inhibitor.
Podaci u 366 bolesnika pokazuju da istovremena primjena inhibitora GP IIb/IIIa ne utječe na ACT.
The safety and efficacy of a bolus dose of bivalirudin without the subsequent infusion has not been evaluated and is not recommended even if a short PCI procedure is planned.
Sigurnost i djelotvornost bolus doze lijeka bivalirudina bez naknadne infuzije nije procijenjena te se ne preporučuje čak ni u slučaju planiranog PCI postupka.
Diluted solution: Chemical and physical in-use stability has been demonstrated for 24 hours at 25
Razrijeđena otopina: Kemijska i fizikalna stabilnost u uporabi dokazana je za 24 sata pri 25
For patients who proceed to CABG surgery on pump, the intravenous infusion of bivalirudin should be continued until 1 hour prior to surgery after which the infusion should be discontinued and the patient treated with unfractionated heparin (UFH).
Kod bolesnika koji idu na operaciju ugradnje srčanih premosnica (CABG) s ekstrakorporalnom cirkulacijom («on-pump»), treba nastaviti s intravenskom infuzijom bivalirudina do jednog sata prije operacije, nakon čega infuziju treba prekinuti i bolesnika liječiti nefrakcioniranim heparinom (unfractionated heparin, UFH).
Arm C bival alone (N=4,612)
Grupa C samo bival (N=4612)
Do not use Angiox
Nemojte primjenjivati Angiox:
Mannitol Sodium hydroxide 2% (for pH adjustment)
Manitol otopina natrijevog hidroksida 2% (za podešavanje pH).
The safety and efficacy of a bolus without subsequent infusion dose of ANGIOX has not been evaluated and is not recommended even if a short PCI procedure is planned.
Sigurnost i djelotvornost bolus doze Angioxa bez naredne doze infuzije nisu utvrđeni i ne preporučuje se čak ni kad je planiran kratki PCI postupak.
Allergic type hypersensitivity reactions were reported uncommonly (≥1/1,000 to ≤1/100) in clinical trials.
U kliničkim ispitivanjima reakcije preosjetljivosti alergijske vrste prijavljene su manje često (≥1/1000 i ≤1/100).
ACUITY trial; bleeding events up to day 30 for the population of patients who received acetylsalicylic acid and clopidogrel as per protocol*
Ispitivanje ACUITY; krvarenja unutar 30 dana za populaciju bolesnika koji su primali acetilsalicilatnu kiselinu i klopidogrel prema planu ispitivanja*
B - A Risk diff. (95% CI)
B - A Razlika rizika (95% CI)
Withdraw 5 ml from the vial, and further dilute in a total volume of 5% 50 ml of glucose solution for injection, or sodium chloride 9 mg/ml (0.9%) solution for injection to give a final bivalirudin concentration of 5 mg/ml.
Zatim izvucite 5 ml otopine iz bočice te je dodatno razrijedite u ukupnom volumenu od 50 ml 5%-tne otopine glukoze za injekcije ili 0,9%-tne (9 mg/ml) otopine natrijevog klorida za injekcije da se dobije konačna koncentracija bivalirudina od 5 mg/ml.
Hälsa Pharma GmbH, Nikolaus Dürkopp-Str. 4A, 33602 Bielefeld, GERMANY
Naziv i adresa proizvođača odgovornog za puštanje serije lijeka u promet Hälsa Pharma GmbH, Nikolaus Dürkopp-Str. 4A, 33602 Bielefeld, NJEMAČKA
• For patients undergoing PCI, bivalirudin MUST be administered initially as an intravenous bolus followed immediately by an infusion.
• Za bolesnike kod kojih se provodi PCI bivalirudin MORA BITI primijenjen početno kao intravenski bolus, nakon čega odmah mora slijediti infuzija.
A total of 17 deaths occurred after subacute stent thrombosis, 3 in the bivalirudin arm and 14 in the UFH plus GP IIb/IIIa arm.
Nakon subakutne tromboze stenta bilo je ukupno 17 smrtnih slučajeva, 3 u bivalirudin grupi ispitanika i 14 u grupi ispitanika UFH s GP IIb/IIIa.
ACUITY scale major bleeding
Ljestvica velikog krvarenja ACUITY
Myocardial infarction,
Infarkt miokarda
C - A Risk diff. (95% CI)
C - A Razlika rizika (95% CI)
A total of 3,602 patients were randomised to receive either bivalirudin (1,800 patients) or unfractionated heparin plus a GP IIb/IIIa inhibitor (1,802 patients).
Randomizirano je ukupno 3602 bolesnika koji su primali ili bivalirudin (1800 bolesnika), ili nefrakcionirani heparin s inhibitorom GP IIb/IIIa (1802 bolesnika).
In any case, when bivalirudin is combined with a platelet inhibitor or an anticoagulant, clinical and biological parameters of haemostasis should be regularly monitored.
U svakom slučaju, kad se bivalirudin kombinira s inhibitorom trombocita ili antikoagulansom, potrebno je redovito nadzirati kliničke i biološke parametre hemostaze.
(see section 4.3 of SmPC).
(vidjeti dio 4.3 Sažetka opisa svojstava lijeka)
Compatible concentrations Incompatible concentrations
Kompatibilne koncentracije
Powder for concentrate for solution for injection or infusion (powder for concentrate).
Prašak za koncentrat za otopinu za injekciju ili infuziju (prašak za koncentrat).
*clopidogrel pre-angiography or pre-PCI
*klopidogrel prije angiografije ili PCI-ja
Any unused solution should be discarded.
Neiskorištenu otopinu potrebno je zbrinuti.
Angiox should be used with caution during beta brachytherapy procedures.
Tijekom postupaka beta brahiterapije Angiox treba koristiti s oprezom.
Uncommon side effects (may affect up to 1 in 100 people): • nausea (feeling sick) and/or vomiting (being sick)
Manje česte nuspojave (mogu zahvatiti do 1 na 100 osoba): • mučnina i/ili povraćanje
The HORIZONS Trial (Patients with STEMI undergoing primary PCI)
Ispitivanje HORIZONS (bolesnici sa STEMI-jem na kojima se provodi primarni PCI)
Patients who are to be medically managed may continue the infusion of 0.25 mg/kg/h for up to 72 hours.
U bolesnika koji su medikamentozno liječeni može se nastaviti s infuzijom od 0,25 mg/kg/sat do 72 sata.
Powder for concentrate for solution for injection or infusion 10 vials
Prašak za koncentrat za otopinu za injekciju ili infuziju 10 bočica
Approximately 23.3% of patients receiving bivalirudin experienced at least one adverse event and 2.1% experienced an adverse reaction.
Otprilike 23,3% bolesnika koji su primali bivalirudin imalo je najmanje jedan štetan događaj, dok je u 2,1% bolesnika došlo do nuspojava.
ACUITY trial; 30-day and 1-year risk differences for the composite ischaemic endpoint and its components for patients that received acetylsalicylic acid and clopidogrel as per protocol*
Table 4. Ispitivanje ACUITY: 30-dnevne i 1-godišnje razlike rizika za ishemijski kompozitni ishod i njegovih komponenata u bolesnika koji su dobivali acetilsalicilatnu kiselinu i klopidogrel prema planu ispitivanja*
Bleeding definitions and outcomes from the REPLACE-2 trial are shown in Table 6.
Definicije krvarenja i ishodi ispitivanja REPLACE-2 prikazani su u tablici 6.
HOW TO STORE ANGIOX
Kako čuvati Angiox
In STEMI patients undergoing primary PCI, standard pre-hospital adjunctive therapy should include clopidogrel and may include the early administration of UFH (See section 5.1).
U bolesnika sa STEMI infarktom koji su podvrgnuti primarnoj PCI, standardna dodatna terapija prije hospitalizacije treba uključivati klopidogrel i može uključivati ranu terapiju nefrakcioniranim heparinom (vidjeti dio 5.1).
The clearance of bivalirudin is similar in patients with normal renal function and those with mild renal impairment.
Klirens bivalirudina sličan je u bolesnika s normalnom funkcijom bubrega i bolesnika s blagim oštećenjem bubrega.
Angiox is also indicated for the treatment of adult patients with unstable angina/non-ST segment elevation myocardial infarction (UA/NSTEMI) planned for urgent or early intervention.
Angiox je također indiciran za liječenje bolesnika s nestabilnom anginom (UA)/infarktom miokarda bez ST-elevacije (NSTEMI) kod kojih se planira hitna ili rana intervencija.
Ferrer-Galenica A.E. Τηλ: +30 210 5281700
Τηλ: +30 210 5281700
Five patients had a post-baseline nadir platelet count of <150,000 cells/mm
Pet bolesnika imalo je najniži broj trombocita nakon početne vrijednosti od <150 000 stanica/mm
As a peptide, bivalirudin is expected to undergo catabolism to its constituent amino acids, with subsequent recycling of the amino acid in the body pool.
Bivalirudin je peptid te se očekuje njegov katabolizam do sastavnih aminokiselina, koje se sakupljaju u tijelu za ponovnu uporabu.
Approximately 30% of patients receiving bivalirudin experienced at least one adverse event and 3% experienced an adverse reaction.
Otprilike 30% bolesnika koji su primali bivalirudin imalo je najmanje jedan štetan događaj, dok je u 3% bolesnika došlo do nuspojava.
The 30-day results based on quadruple and triple endpoints from a randomized, double-blind trial of over 6,000 patients undergoing PCI (REPLACE-2) are shown in Table 5.
Tridesetodnevni rezultati (REPLACE-2) istraživanja, prikazani su u tablici 5. Radi se o randomiziranom, dvostruko slijepom ispitivanju s preko 6000 bolesnika podvrgnutih PCI, koje je temeljeno na četverostrukim i trostrukim ishodima.
If you need to have a coronary artery bypass graft operation, treatment with bivalirudin will either be stopped one hour before the operation or an additional dose of 0.5 mg/kg body weight will be given by injection followed by an infusion of 1.75 mg/kg body weight per hour for the duration of surgery.
Ako trebate ići na operaciju premoštenja koronarnih arterija, liječenje bivalirudinom bit će prekinuto jedan sat prije operacije ili će Vam biti dana injekcija dodatne doze od 0,5 mg/kg tjelesne težine nakon čega će uslijediti infuzija brzinom od 1,75 mg/kg tjelesne težine na sat tijekom trajanja operacije.
• In patients with moderate renal impairment (GFR 30-59 ml/ min) the infusion rate should be reduced to 1.4 mg/kg/h.
• U bolesnika s umjerenim oštećenjem bubrežne funkcije (GFR 30-59 ml/ min) brzina infuzije mora se smanjiti na 1,4 mg/kg/h.
The following medicinal products should not be administered in the same intravenous line as bivalirudin since they result in haze formation, micro-particulate formation or gross precipitation; alteplase, amiodarone HCl, amphotericin B, chlorpromazine hydrochloride (HCl), diazepam, prochlorperazine edisylate, reteplase, streptokinase and vancomycin HCl.
Sljedeći lijekovi ne smiju se davati u istoj intravenskoj liniji s bivalirudinom jer uzrokuju mutnoću, formiranje mikročestica ili grubo taloženje: alteplaza, amiodaronklorid, amfotericin B, klorpromazin klorid (HCl), diazepam, proklorperazinedisilat, reteplaza, streptokinaza i vankomicinklorid.
Coronary artery thrombosis and coronary stent thrombosis with myocardial infarction, and catheter thrombosis have each been reported rarely.
Tromboza koronarne arterije i tromboza koronarnog stenta s infarktom miokarda te tromboza katetera rijetko su zabilježene.
Angiox should be initially reconstituted to give a solution of 50 mg/ml bivalirudin.
Angiox treba prvo rekonstituirati da se dobije otopina od 50 mg/ml bivalirudina.
Serious adverse reactions were reported more frequently in the heparin plus GP IIb/IIIa group than the bivalirudin treated group.
Ozbiljne nuspojave prijavljene su češće u grupi liječenoj heparinom s GP IIb/IIIa, nego u grupi ispitanika koja je dobivala bivalirudin.
The medicinal products incompatible with bivalirudin at higher concentrations are: dobutamine hydrochloride, famotidine, haloperidol lactate, labetalol hydrochloride, lorazepam and promethazine HCl.
Lijekovi koji su inkompatibilni s bivalirudinom kod viših koncentracija su: dobutaminklorid, famotidin, haloperidol laktat, labetalolklorid, lorazepam i prometazinklorid.
3, representing a ≥50% decrease in platelets from baseline.
3, što predstavlja smanjenje broja trombocita od ≥50% u odnosu na početnu vrijednost.
Bleeding definitions and outcomes from the HORIZONS trial are shown in Table 6.
Definicije krvarenja i ishoda ispitivanja HORIZONS prikazani su u tablici 6.
In Arm A of the ACUITY trial, UFH or enoxaparin was administered in accordance with the relevant guidelines for the management of ACS in patients with UA and NSTEMI.
Grupi ispitanika A u ispitivanju ACUITY bio je dan nefrakcionirani heparin ili enoksaparin u skladu s relevantnim smjernicama liječenja ACS-a u bolesnika s nestabilnom anginom i NSTEMI.
For patients who proceed to coronary artery bypass graft (CABG) surgery off pump, the intravenous infusion of bivalirudin should be continued until the time of surgery.
Kod bolesnika koji idu na operaciju ugradnje srčanih premosnica (coronary artery bypass graft, CABG) bez ekstrakorporalne cirkulacije («off pump»), treba nastaviti s intravenskom infuzijom bivalirudina do vremena operacije.
Common side effects (may affect up to 1 in 10 people):
Česte nuspojave (mogu zahvatiti do 1 na 10 osoba):
Co-administration with platelet inhibitors or anti-coagulants
Istovremena primjena inhibitora trombocita ili antikoagulansa
In patients with mild or moderate renal insufficiency, the ACS dose (0.1 mg/kg bolus/0.25 mg/kg/h infusion) should not be adjusted.
U bolesnika s blagom ili umjerenom bubrežnom insuficijencijom ne treba prilagoditi dozu za ACS (bolus 0,1 mg/kg/infuzija 0,25 mg/kg/sat).
Bleeding has been observed in some reports of overdose.
U nekim izvješćima o predoziranju, opaženo je krvarenje.
Reconstituted solution: Chemical and physical in-use stability has been demonstrated for 24 hours at 2-8C.
Rekonstituirana otopina: Kemijska i fizikalna stabilnost u uporabi dokazana je za 24 sata pri 2-8
Angiox contains sodium
Angiox sadrži natrij
• In patients receiving warfarin, INR is increased by administration of bivalirudin.
• U bolesnika koji primaju varfarin primjenom bivalirudina povećava se INR.
Rare (≥1/10,000 to
Rijetko (≥1/10 000 i
Reperfusion injury (no or slow reflow), Contusion a. ADRs identified in post-marketing experience b. Compartment syndrome has been reported as a complication of forearm haematoma following administration of bivalirudin via the radial access route in post-marketing experience c. Further detail regarding stent thrombosis is provided in section 4.8: The HORIZONS Trial (Patients with STEMI undergoing primary PCI).
Kompartment sindrom bio je, prema postmarketinškom iskustvu, zabilježen kao komplikacija hematoma podlaktice nakon primjene bivalirudina radijalnim pristupom c. Više detalja u vezi s trombozom stenta prikazano je u dijelu 4.8: Ispitivanje HORIZONS (bolesnici sa STEMIjem na kojima se provodi primarni PCI).
Angiox contains less than 1 mmol sodium (23 mg) per vial, i.e. essentially “sodium-free”.
Pomoćna tvar Angiox sadrži manje od 1 mmol natrija (23 mg) po bočici, tj. zanemarive količine natrija.
Angiox is intended for intravenous use.
Način primjene Angiox je namijenjen intravenskoj primjeni.
Angiox is contraindicated in patients with severe renal insufficiency (GFR<30 ml/min) and also in dialysis-dependent patients (see section 4.3).
Angiox je kontraindiciran u bolesnika s teškom bubrežnom insuficijencijom (GFR <30 ml/min), kao i u bolesnika koji ovise o dijalizi (vidjeti dio 4.3).
In healthy volunteers and patients, bivalirudin exhibits dose- and concentration-dependent anticoagulant activity as evidenced as prolongation of the ACT, aPTT, PT, INR and TT. Intravenous administration of bivalirudin produces measurable anticoagulation within minutes.
U zdravih dobrovoljaca i bolesnika, bivalirudin pokazuje antikoagulantnu aktivnost koja je ovisna o dozi i koncentraciji, što se očituje produljenjem ACT-a, APTV-a, PV-a, INR-a, ITV-a.
If you have any further questions on the use of this medicine, ask your doctor.
Obratite se liječniku ako imate više pitanja o uporabi ovog lijeka.
The recommended starting dose of bivalirudin for medically managed patients with acute coronary syndrome (ACS) is an intravenous bolus of 0.1 mg/kg followed by an infusion of 0.25 mg/kg/h.
Preporučena početna doza bivalirudina za medikamentozno liječene bolesnike s akutnim koronarnim sindromom (ACS-om) je intravenski bolus od 0,1 mg/kg nakon čega slijedi infuzija od 0,25 mg/kg/sat.
The dose of bivalirudin used in HORIZONS was the same as that used in the REPLACE-2 study (0.75 mg/kg bolus followed by a 1.75 mg/kg body weight/hour infusion).
Primijenjena doza bivalirudina u ispitivanju HORIZONS bila je ista kao i za ispitivanje REPLACE-2 (bolus od 0,75 mg/kg nakon čega je uslijedila infuzija od 1,75 mg/kg tjelesne težine/sat).
Lyophilised (freeze-dried) powder: Do not store above 25C.
Liofilizirani (osušen smrzavanjem) prašak: Ne čuvati na temperaturi iznad 25 C.
Angiox 250 mg powder for concentrate for solution for injection or infusion.
Angiox 250 mg prašak za koncentrat za otopinu za injekciju ili infuziju.
The bolus dose remains 0.75 mg/kg (or 0.5 mg/kg in patients who proceed to PCI after receiving bivalirudin pre-cath lab (UA/NSTEMI)).
Bolus doza ostaje 0,75 mg/kg (ili 0,5 mg/kg u bolesnika koji idu na PCI nakon što su primili bivalirudin prije kateterizacije (UA/NSTEMI)).
The majority of these patients received concomitant acetylsalicylic acid and clopidogrel, and 10 out of 20 patients also received a GP IIb/IIIa inhibitor.
Većina ovih bolesnika istovremeno je primila acetilsalicilatnu kiselinu i klopidogrel, a 10 od 20 bolesnika su također dobivali i inhibitor GP IIb/IIIa.
Blood and lymphatic system disorders
Poremećaji krvi i limfnog sustava trombocitopenija,
The bolus dose remains 0.75 mg/kg; or 0.5 mg/kg in patients who proceed to PCI after receiving bivalirudin pre-cath lab (UA/NSTEMI).
Bolus doza ostaje 0,75 mg/kg; ili 0,5 mg/kg u bolesnika koji koji idu na PCI nakon što su primili bivalirudin prije kateterizacije (UA/NSTEMI).
Patients undergoing PCI, including patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary PCI
Bolesnici koji se podvrgavaju perkutanoj koronarnoj intervenciji (PCI), uključujući bolesnike s infarktom miokarda sa ST-elevacijom (STEMI) podvrgnute primarnom PCI-ju
The following data are based on a clinical study of bivalirudin in patients with STEMI undergoing primary PCI; 1,800 patients were randomised to bivalirudin alone, 1,802 were randomised to heparin plus GP IIb/IIIa inhibitor.
Sljedeći su podaci temeljeni na kliničkom ispitivanju s bivalirudinom u bolesnika sa STEMI-jem u kojih se provodi primarni PCI; 1800 bolesnika je randomizirano samo za bivalirudin, 1802 bolesnika je randomizirano za heparin s inhibitorom GP IIb/IIIa.
Clinical trials in a small number of patients have provided limited information about the use of Angiox in patients with HIT/HITTS.
Klinička ispitivanja s malim brojem bolesnika dala su ograničene informacije o uporabi Angioxa u bolesnika s trombocitopenijom uzrokovanom heparinom i sindromom trombocitopenije/tromboze uzrokovane heparinom.
Brachytherapy
Brahiterapija
these medicines may increase the risk of side effects such as bleeding when given at the same time as Angiox.
Ako se daju istovremeno kad i Angiox, ti lijekovi mogu povećati opasnost od nuspojava kao što je krvarenje.
The majority of these patients received concomitant acetylsalicylic acid and clopidogrel, and 6 out of the 10 patients also received a GP IIb/IIIa inhibitor.
Većina ovih bolesnika istovremeno je primila acetilsalicilatnu kiselinu i klopidogrel, a 6 od 10 bolesnika dobivali su i inhibitor GP IIb/IIIa.
• Approved dose in patients undergoing percutaneous coronary intervention (PCI): The licensed and approved dosing regimen of Angiox is an intravenous (IV) bolus injection of 0.75 mg/kg body weight followed immediately by an intravenous infusion at 1.75 mg/kg/hour for at least the duration of the PCI.
• Odobrenu dozu u bolesnika kod kojih se provodi perkutana koronarna intervencija (PCI): Licenciran i odobren raspored doziranja Angioxa je intravenska (i.v.) bolus injekcija od 0,75 mg/kg tjelesne težine nakon čega odmah slijedi intravenska infuzija pri 1,75 mg/kg/sat, barem tijekom trajanja PCI-ja.
Major bleeding rates for the intent-to-treat trial population are shown in Table 6.
Stope velikih krvarenja u ispitivanoj populaciji s namjerom liječenja (ITT) prikazane su u tablici 6.
A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE
PROIZVOĐAČ(I) ODGOVORAN(ODGOVORNI) ZA PUŠTANJE
Heparin-induced thrombocytopenia (HIT) and heparin-induced thrombocytopenia-thrombosis syndrome (HIT/HITTS)
Trombocitopenija uzrokovana heparinom i sindrom trombocitopenije/tromboze uzrokovan heparinom
Major bleeding rates in clinical trials of bivalirudin 30 day endpoints for intent-to
Tablica 6. Stope velikih krvarenja u 30-dnevnim ishodima kliničkih ispitivanjima s bivalirudinom u populaciji s namjerom liječenja.
Your treatment with Angiox will be supervised by a doctor.
Liječnik će nadzirati Vaše liječenje Angioxom.
In ACUITY, bleeding data were collected separately from adverse reactions.
U ACUITY ispitivanju podaci o krvarenju sakupljani su odvojeno od nuspojava.
After being treated with Angiox for a cardiac event, you should stay in the hospital for at least 24 hours and you should be monitored for any symptoms or signs similar to the ones that remind you of your cardiac event and resulted in your hospitalisation.
Vas se nadzirati na bilo koje simptome ili znakove slične onima koji Vas podsjećaju na Vaš srčani događaj zbog čega ste i primljeni u bolnicu.
The solution should be a clear to slightly opalescent, colourless to slightly yellow solution.
Otopina treba biti bistra do blago opalescentna, bezbojna do blago žuta.
In Arms B and C of the ACUITY trial, the recommended dose of bivalirudin was an initial postrandomisation intravenous bolus of 0.1 mg/kg followed by a continuous intravenous infusion of 0.25 mg/kg/h during angiography or as clinically warranted.
U grupama B i C ispitivanja ACUITY preporučena doza bivalirudina bila je kako slijedi: početni postrandomizacijski intravenski bolus od 0,1 mg/kg, nakon čega je uslijedila kontinuirana intravenskainfuzija od 0,25 mg/kg/sat tijekom angiografije ili kako je to zahtijevala klinička slika.
All of these bivalirudintreated patients received concomitant acetylsalicylic acid, all but 1 received clopidogrel and 15 also received a GP IIb/IIIa inhibitor.
Svi bolesnici liječeni bivalirudinom primali su istovremeno i acetilsalicilatnu kiselinu, svi osim jednog primali su klopidogrel, a njih je 15 također primalo inhibitor GP IIb/IIIa.
Angiox is a white to off-white powder in a glass vial.
Angiox je prašak za koncentrat za otopinu za injekciju ili infuziju (prašak za koncentrat) Angiox je bijeli do gotovo bijeli prašak u staklenoj bočici.
The incidence of major and minor bleeding was significantly less in patients treated with bivalirudin versus patients treated with heparin plus a GP IIb/IIIa inhibitor.
Incidencija velikih i malih krvarenja bila je značajno manja u bolesnika liječenih bivalirudinom naspram bolesnika liječenih heparinom i inhibitorom GP IIb/IIIa.
Angiox 250 mg powder for concentrate for solution for injection or infusion bivalirudin
Angiox 250 mg prašak za koncentrat za otopinu za injekciju ili infuziju bivalirudin
In the HORIZONS study both major and minor bleeding occurred commonly (1/100 and <1/10).
Velika i mala krvarenja često su se pojavljivala u ispitivanju HORIZONS (1/100 i <1/10).